Maravai’s revenue guidance for the full year 2025 is based on expectations for its existing base business and does not include revenue, if any, from high-volume CleanCap orders for commercial phase vaccine programs, or potential new acquisitions, if any, or items that have not yet been identified or quantified.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- MRVI Upcoming Earnings Report: What to Expect?
- MRVI Lawsuit Alert! Class Action Lawsuit Against Maravai Lifesciences Holdings
- Maravai Lifesciences price target lowered to $5 from $7 at Morgan Stanley
- Maravai LifeSciences Earnings Call: Growth Amid Challenges
- Biotech Alert: Searches spiking for these stocks today